https://www.pharmaradar360.com/article/west-pharmaceutical-stock-holds-moderate-buy-rating-as-annex-1-work-shapes-outlo-3c0fd62fb4220ec9PharmaRadar360en2026-09-19T15:29:24.000ZWest Pharmaceutical stock holds Moderate Buy rating as Annex 1 work shapes outlookhttps://www.pharmaradar360.com/article/secret-contracts-reveal-undisclosed-terms-in-trump-s-drug-pricing-deals-bcbb413fb30f9d63PharmaRadar360en2026-09-19T14:32:27.000ZSecret contracts reveal undisclosed terms in Trump’s drug-pricing dealshttps://www.pharmaradar360.com/article/oncolytics-biotech-stock-lacks-a-fresh-catalyst-and-stays-near-0-77-4ef9f2145181d3bbPharmaRadar360en2026-09-19T14:17:54.000ZOncolytics Biotech stock lacks a fresh catalyst and stays near $0.77https://www.pharmaradar360.com/article/what-is-drawing-fresh-attention-to-biomarin-pharmaceutical-bmrn-dd7670b3b7f47046PharmaRadar360en2026-09-19T14:12:22.000ZWhat Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)?https://www.pharmaradar360.com/article/how-investors-are-reacting-to-ultragenyx-pharmaceutical-rare-first-in-disease-ge-39556364aa63f8c2PharmaRadar360en2026-09-19T14:10:33.000ZHow Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVIhttps://www.pharmaradar360.com/article/oveporexton-met-primary-key-secondary-end-points-in-phase-3-studies-f55b262789759abcPharmaRadar360en2026-09-19T14:10:03.000ZOveporexton Met Primary, Key Secondary End Points in Phase 3 Studieshttps://www.pharmaradar360.com/article/collegium-pharmaceutical-stock-edges-lower-as-analysts-keep-moderate-buy-stance-474386a21dda61b3PharmaRadar360en2026-09-19T13:33:57.000ZCollegium Pharmaceutical stock edges lower as analysts keep Moderate Buy stancehttps://www.pharmaradar360.com/article/stanford-s-virtual-biotech-turns-37-000-ai-agents-into-a-drug-discovery-factory-6211ed771f1838afPharmaRadar360en2026-09-19T13:23:02.000ZStanford's Virtual Biotech turns 37,000 AI agents into a drug-discovery factoryhttps://www.pharmaradar360.com/article/passaparola-21-09-120-anni-della-clinica-mangiagalli-celebriamo-la-culla-d-itali-b6f1cc699352db07PharmaRadar360en2026-09-19T13:00:00.000Z#PASSAPAROLA [21.09] 120 anni della Clinica Mangiagalli: celebriamo la culla d’Italiahttps://www.pharmaradar360.com/article/opthea-limited-stock-steadies-as-phase-3-trial-progress-drives-investor-focus-7dd5c0af77aa118aPharmaRadar360en2026-09-19T12:29:41.000ZOpthea Limited stock steadies as phase 3 trial progress drives investor focushttps://www.pharmaradar360.com/article/macrogenics-stock-edges-lower-as-biotech-analysts-highlight-risk-and-upside-e9cf4e74587d279dPharmaRadar360en2026-09-19T12:15:12.000ZMacroGenics stock edges lower as biotech analysts highlight risk and upsidehttps://www.pharmaradar360.com/article/rassegnastampa-tumori-in-eta-pediatrica-favorire-le-prospettive-di-guarigione-ne-533dc6a088ec60cePharmaRadar360en2026-09-19T11:58:00.000Z#RASSEGNASTAMPA. Tumori in età pediatrica: favorire le prospettive di guarigione. Ne parla Ernesto Leva a TG4 Medicinahttps://www.pharmaradar360.com/article/latus-bio-adds-biotech-veterans-as-gene-therapies-enter-clinic-d758e89343372953PharmaRadar360en2026-09-19T11:37:30.000ZLatus Bio Adds Biotech Veterans as Gene Therapies Enter Clinichttps://www.pharmaradar360.com/article/chip-tech-to-biotech-ce2e02f56139299fPharmaRadar360en2026-09-19T11:30:00.000ZChip tech to biotechhttps://www.pharmaradar360.com/article/basic-earnings-per-share-basic-eps-of-indrayani-biotech-ltd-right-2026-25-06-26-6078a04cee3109b7PharmaRadar360en2026-09-19T11:26:00.000ZBasic earnings per share (basic EPS) of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32PharmaRadar360en2026-09-19T10:52:34.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/veraxa-biotech-vrxa-insider-trading-activity-2026-249623a1453a3bf2PharmaRadar360en2026-09-19T10:43:00.000ZVeraxa Biotech (VRXA) Insider Trading Activity 2026https://www.pharmaradar360.com/article/top-10-pharmaceutical-manufacturing-companies-in-africa-in-2026-b4a1093df370deb8PharmaRadar360en2026-09-19T10:42:10.000ZTop 10 Pharmaceutical Manufacturing Companies in Africa in 2026https://www.pharmaradar360.com/article/emirates-biotech-uae-university-partner-on-food-waste-plant-for-biogas-compost-5fbfd1099eb088dbPharmaRadar360en2026-09-19T10:33:23.000ZEmirates Biotech, UAE University partner on food waste plant for biogas, composthttps://www.pharmaradar360.com/article/cassava-sciences-stock-holds-near-recent-lows-as-biotech-losses-and-mixed-sentim-d4ec6f7ef586a00bPharmaRadar360en2026-09-19T10:10:12.000ZCassava Sciences stock holds near recent lows as biotech losses and mixed sentiment weighhttps://www.pharmaradar360.com/article/tirupati-group-appoints-uday-k-potdar-as-chief-financial-officer-339f006e241d5b8dPharmaRadar360en2026-09-19T10:01:43.000ZTirupati Group Appoints Uday K. Potdar As Chief Financial Officerhttps://www.pharmaradar360.com/article/karnataka-approves-marine-biotech-policy-targets-6-8-bn-blue-bioeconomy-by-2031-2fb7e60f353058d0PharmaRadar360en2026-09-19T10:00:20.000ZKarnataka approves marine biotech policy, targets $6-8 bn blue bioeconomy by 2031https://www.pharmaradar360.com/article/another-novartis-failure-novo-drops-the-nordisk-and-more-12d3d548f946c7a8PharmaRadar360en2026-09-19T10:00:00.000ZAnother Novartis failure; Novo drops the ‘Nordisk’; and morehttps://www.pharmaradar360.com/article/vaccinex-stock-holds-at-1-00-dollars-as-investors-await-fresh-trial-and-earnings-e39c8770527cfb72PharmaRadar360en2026-09-19T09:32:43.000ZVaccinex stock holds at 1.00 dollars as investors await fresh trial and earnings updateshttps://www.pharmaradar360.com/article/ordinary-people-pay-price-iran-medicine-shortages-deepen-as-war-continues-25bdcfd142278adePharmaRadar360en2026-09-19T09:30:32.000Z‘Ordinary people pay price’: Iran medicine shortages deepen as war continueshttps://www.pharmaradar360.com/article/medicine-shortages-deepen-in-iran-amid-war-shipping-restrictions-1722387ef29ee867PharmaRadar360en2026-09-19T08:18:00.000ZMedicine shortages deepen in Iran amid war, shipping restrictionshttps://www.pharmaradar360.com/article/ganpati-meets-food-safety-navi-mumbai-pandal-honours-tukaram-mundhes-fda-work-wi-8edca60af6c53510PharmaRadar360en2026-09-19T07:37:17.000ZGanpati Meets Food Safety! Navi Mumbai Pandal Honours Tukaram Mundhes FDA Work With Unique Ganesh Decor Themehttps://www.pharmaradar360.com/article/equity-in-earnings-of-zhuhai-trinomab-pharmaceutical-co-ltd-class-a-sse-688806-e04ee5f175d57b5aPharmaRadar360en2026-09-19T07:27:52.000ZEquity in earnings of Zhuhai Trinomab Pharmaceutical Co., Ltd. Class A – SSE:688806https://www.pharmaradar360.com/article/price-to-book-forward-of-henan-taloph-pharmaceutical-stock-co-ltd-class-a-sse-60-2bc42da5d2afe758PharmaRadar360en2026-09-19T07:27:29.000ZPrice to book forward of Henan Taloph Pharmaceutical Stock Co. Ltd. Class A – SSE:600222https://www.pharmaradar360.com/article/teva-s-tev-749-olanzapine-lai-shows-80-stabilization-rate-in-schizophrenia-trial-90a9d7a77742a0d4PharmaRadar360en2026-09-19T06:42:48.000ZTeva’s TEV-749 olanzapine LAI shows 80% stabilization rate in schizophrenia trialhttps://www.pharmaradar360.com/article/fda-approves-imlunestrant-plus-abemaciclib-for-esr1-mutated-breast-cancer-3c625593f647ec48PharmaRadar360en2026-09-19T06:37:48.000ZFDA approves imlunestrant plus abemaciclib for ESR1-mutated breast cancerhttps://www.pharmaradar360.com/article/alumna-employs-biotech-to-create-sustainable-livestock-production-f241526028de166dPharmaRadar360en2026-09-19T06:00:00.000ZAlumna employs biotech to create sustainable livestock productionhttps://www.pharmaradar360.com/article/iraq-customs-clarifies-duties-on-pharmaceuticals-vitamins-and-supplements-8cc25463c2e436b0PharmaRadar360en2026-09-19T05:13:48.000ZIraq Customs clarifies duties on pharmaceuticals, vitamins, and supplementshttps://www.pharmaradar360.com/article/pharmtech-weekly-roundup-september-18-2026-177f47cf9e1b228bPharmaRadar360en2026-09-19T05:07:01.000ZPharmTech Weekly Roundup—September 18, 2026https://www.pharmaradar360.com/article/welcome-to-the-mammosphere-f5899a492f6d03cdPharmaRadar360en2026-09-19T02:45:14.000ZWelcome to the mammospherehttps://www.pharmaradar360.com/article/how-annex-1-upgrades-at-west-pharmaceutical-services-wst-have-changed-its-invest-c6d42c01254a7c15PharmaRadar360en2026-09-19T02:42:21.000ZHow Annex 1 Upgrades At West Pharmaceutical Services (WST) Have Changed Its Investment Storyhttps://www.pharmaradar360.com/article/astrazeneca-halts-one-lung-cancer-trial-after-mixed-phase-3-results-aba6e0c9f3b21761PharmaRadar360en2026-09-19T02:26:43.000ZAstraZeneca halts one lung cancer trial after mixed Phase 3 resultshttps://www.pharmaradar360.com/article/fda-hearing-psychedelics-launch-needs-balanced-regulation-without-limiting-acces-81cc63fd87c8c2d5PharmaRadar360en2026-09-19T02:15:00.000ZFDA hearing: psychedelics launch needs balanced regulation without limiting accesshttps://www.pharmaradar360.com/article/homilia-te-deum-una-casa-edificada-sobre-roca-470e28c9f1d5d8c9PharmaRadar360en2026-09-19T00:08:42.000ZHomilía Te Deum: Una casa edificada sobre rocahttps://www.pharmaradar360.com/article/transarterial-infusion-chemotherapy-and-embolization-as-a-novel-neoadjuvant-ther-7aac60eaf852135bPharmaRadar360en2026-09-19T00:00:00.000ZTransarterial infusion chemotherapy and embolization as a novel neoadjuvant therapy for locally advanced gastric cancer: a prospective single-arm pilot studyhttps://www.pharmaradar360.com/article/neo-bcv-induces-macrophage-associated-immunometabolic-remodeling-and-anti-tumor-0c165255b6a8071fPharmaRadar360en2026-09-19T00:00:00.000ZNeo-BCV induces macrophage-associated immunometabolic remodeling and anti-tumor immunity in solid tumorshttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-92f3d478f9a9a803PharmaRadar360en2026-09-19T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-30d05734be2b8565PharmaRadar360en2026-09-19T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-22ff2a568dabf918PharmaRadar360en2026-09-19T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-de70afab94ee6db7PharmaRadar360en2026-09-19T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-f1fd06fc7a374965PharmaRadar360en2026-09-19T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-27c52285a30f9bc6PharmaRadar360en2026-09-19T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-8f9e69afd0cb053dPharmaRadar360en2026-09-19T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-efef70c7d026f41bPharmaRadar360en2026-09-19T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-8afc627e4579d5d4PharmaRadar360en2026-09-19T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-e5df46ac20c2e888PharmaRadar360en2026-09-19T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-be70b46a60b900cdPharmaRadar360en2026-09-19T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-e267ca8d0ce77a01PharmaRadar360en2026-09-19T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-b34380177a22639aPharmaRadar360en2026-09-19T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-ef59172569822192PharmaRadar360en2026-09-19T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/safe-medicine-storage-and-disposal-among-pharmacy-and-engineering-students-a-kap-e3e2d4de32f25ed1PharmaRadar360en2026-09-19T00:00:00.000ZSafe Medicine Storage and Disposal among Pharmacy and Engineering Students: A Kap Study with Pre-Post Knowledge Assessmenthttps://www.pharmaradar360.com/article/mpox-outbreak-in-cote-d-ivoire-during-2024-epidemiological-clinical-virological-2027dc5ac6527c47PharmaRadar360en2026-09-19T00:00:00.000ZMpox Outbreak in Côte d'Ivoire during 2024: Epidemiological, Clinical, Virological and Outcome Features of Hospitalised Cases in Abidjanhttps://www.pharmaradar360.com/article/regenerative-medicine-in-the-management-of-musculoskeletal-pain-mechanisms-clini-d650a4d034f3b544PharmaRadar360en2026-09-19T00:00:00.000ZRegenerative Medicine in the Management of Musculoskeletal Pain: Mechanisms, Clinical Applications, and Future Directionshttps://www.pharmaradar360.com/article/clinical-efficacy-of-minimally-invasive-technologies-in-the-treatment-of-obstruc-b2e082ddcb04ca29PharmaRadar360en2026-09-19T00:00:00.000ZCLINICAL EFFICACY OF MINIMALLY INVASIVE TECHNOLOGIES IN THE TREATMENT OF OBSTRUCTIVE JAUNDICE ASSOCIATED WITH CHOLEDOCHOLITHIASIShttps://www.pharmaradar360.com/article/the-role-of-physicians-in-child-and-adolescent-psychiatry-exploring-the-therapeu-95303ae91b93ede6PharmaRadar360en2026-09-19T00:00:00.000ZThe Role of Physicians in Child and Adolescent Psychiatry: Exploring the Therapeutic Potential of Herbal Remedieshttps://www.pharmaradar360.com/article/examination-of-international-strategies-and-collaborative-efforts-in-responding-dcbf1a1c7f477fb6PharmaRadar360en2026-09-19T00:00:00.000ZExamination of International Strategies and Collaborative Efforts in Responding to the Ebola Crisis in West Africa: Lessons from the 2026 Bundibugyo Outbreak in the Democratic Republic of the Congo and Ugandahttps://www.pharmaradar360.com/article/efficacy-of-gs-441524-in-the-management-of-feline-infectious-peritonitis-a-clini-2b94abafbc0802b3PharmaRadar360en2026-09-19T00:00:00.000ZEfficacy of GS-441524 in the Management of Feline Infectious Peritonitis: A Clinical Studyhttps://www.pharmaradar360.com/article/serum-nfl-and-gfap-levels-and-their-association-with-anxiety-depression-in-alzhe-38114244d078d939PharmaRadar360en2026-09-19T00:00:00.000ZSerum NfL and GFAP levels and their association with anxiety-depression in Alzheimer’s disease patients: A clinical retrospective studyhttps://www.pharmaradar360.com/article/takotsubo-syndrome-a-review-of-psychobiological-mechanisms-and-clinical-practice-796f14de12226badPharmaRadar360en2026-09-19T00:00:00.000ZTakotsubo syndrome: A review of psychobiological mechanisms and clinical practice interventionshttps://www.pharmaradar360.com/article/from-correlation-to-intervention-translating-the-psychological-network-of-adoles-b02a37b1b055f61ePharmaRadar360en2026-09-19T00:00:00.000ZFrom correlation to intervention: Translating the psychological network of adolescent non-suicidal self-injury into clinical practicehttps://www.pharmaradar360.com/article/lt-b-gt-thiet-lap-ca-hai-tham-so-cua-bieu-o-kiem-soat-noi-kiem-hanh-lang-can-tre-a089bde4f7254a16PharmaRadar360en2026-09-19T00:00:00.000Z&lt;b&gt;THIẾT LẬP CẢ HAI THAM SỐ CỦA BIỂU ĐỒ KIỂM SOÁT NỘI KIỂM: HÀNH LANG CẬN TRÊN-CẬN DƯỚI CỦA ĐỘ KHÔNG CHỤM CHO GIỚI HẠN VÀ ĐỐI CHIẾU NGOẠI KIỂM CHO TRUNG BÌNH - NGHIÊN CỨU TRÊN 24 XÉT NGHIỆM HOÁ SINH&lt;/b&gt;https://www.pharmaradar360.com/article/lt-b-gt-khao-sat-chi-so-triglyceride-glucose-lt-b-gt-lt-b-gt-tyg-lt-b-gt-lt-b-gt-9aa3330e763554d0PharmaRadar360en2026-09-19T00:00:00.000Z&lt;b&gt;KHẢO SÁT CHỈ SỐ TRIGLYCERIDE-GLUCOSE&lt;/b&gt;&lt;b&gt; (TYG)&lt;/b&gt;&lt;b&gt; VÀ MỐI LIÊN QUAN VỚI MỘT SỐ &lt;/b&gt;&lt;b&gt;&lt;/b&gt; &lt;b&gt;ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG Ở BỆNH NHÂN GOUT &lt;/b&gt;&lt;b&gt;&lt;/b&gt;https://www.pharmaradar360.com/article/beyond-the-site-of-pain-fascial-continuity-and-integrated-clinical-reasoning-in-0df9516427501ea6PharmaRadar360en2026-09-19T00:00:00.000ZBEYOND THE SITE OF PAIN: FASCIAL CONTINUITY AND INTEGRATED CLINICAL REASONING IN MANUAL THERAPYhttps://www.pharmaradar360.com/article/proenkephalin-penkid-in-renal-dysfunction-an-integrative-review-of-laboratory-an-93660ff9cfd11b01PharmaRadar360en2026-09-19T00:00:00.000ZProenkephalin/penKid in renal dysfunction: An integrative review of laboratory and clinical evidencehttps://www.pharmaradar360.com/article/regenerative-medicine-at-the-crossroads-of-innovation-evidence-and-clinical-resp-05677a7f689b1c65PharmaRadar360en2026-09-19T00:00:00.000ZRegenerative medicine at the crossroads of innovation, evidence, and clinical responsibilityhttps://www.pharmaradar360.com/article/clinical-and-laboratory-profile-of-i-mycoplasma-pneumoniae-i-pneumonia-among-chi-552f7c94137766f9PharmaRadar360en2026-09-19T00:00:00.000ZClinical and Laboratory Profile of <i>Mycoplasma pneumoniae</i> Pneumonia among Children Aged 1 Month to 18 Years for 2 Years Admitted in a Tertiary Care Center: A Retrospective Studyhttps://www.pharmaradar360.com/article/inguinal-hernia-as-a-systemic-enzyme-dysfunction-disorder-a-prospective-comparat-e64f9953548400b0PharmaRadar360en2026-09-19T00:00:00.000ZInguinal Hernia as a Systemic Enzyme Dysfunction Disorder: A Prospective Comparative Study on the Role of Matrix Metalloproteinase-9 in The Transversalis Fasciahttps://www.pharmaradar360.com/article/the-psychological-impact-of-covid-19-and-mental-relaxation-practices-by-amateur-073b7c79da9ccae2PharmaRadar360en2026-09-19T00:00:00.000ZThe Psychological Impact of COVID -19 and Mental Relaxation Practices by Amateur Boxers: A Qualitative Studyhttps://www.pharmaradar360.com/article/ethnomedicinal-utilization-of-rauwolfia-serpentina-l-benth-ex-kurz-7d5ee8c80c1d7646PharmaRadar360en2026-09-19T00:00:00.000ZEthnomedicinal utilization of Rauwolfia serpentina (L.) Benth. ex Kurzhttps://www.pharmaradar360.com/article/computational-exploration-revealed-nicotiflorin-as-a-potent-dpp4-inhibitor-for-d-5a77b6dc254be1b5PharmaRadar360en2026-09-19T00:00:00.000ZComputational exploration revealed Nicotiflorin as a potent DPP4 inhibitor for diabetes management: Insights from network pharmacology, molecular docking, and molecular dynamics simulations studieshttps://www.pharmaradar360.com/article/development-and-validation-of-a-reverse-phase-high-performance-liquid-chromatogr-ec3e92366fb1a9cePharmaRadar360en2026-09-19T00:00:00.000ZDevelopment and Validation of A Reverse Phase High Performance Liquid Chromatography (Rp-Hplc) Method for The Estimation of Process Related Impurity from Lobeglitazone Sulfatehttps://www.pharmaradar360.com/article/citrate-versus-heparin-anticoagulation-during-crrt-with-mg350-hemoadsorption-in-fd82283ab4495bfcPharmaRadar360en2026-09-19T00:00:00.000ZCitrate versus heparin anticoagulation during CRRT with MG350 hemoadsorption in critically ill patients: a randomized controlled trial protocolhttps://www.pharmaradar360.com/article/clinical-profile-and-treatment-outcomes-of-pleural-effusion-and-empyema-thoracis-bbe452d5da9517d3PharmaRadar360en2026-09-19T00:00:00.000ZClinical Profile and Treatment Outcomes of Pleural Effusion and Empyema Thoracis in a Tertiary Hospital of Bangladeshhttps://www.pharmaradar360.com/article/factors-associated-with-lymphoma-recurrence-following-autologous-stem-cell-trans-bcec6940d14004dbPharmaRadar360en2026-09-19T00:00:00.000ZFactors Associated with Lymphoma Recurrence Following Autologous Stem Cell Transplantationhttps://www.pharmaradar360.com/article/phytochemical-dark-matter-unlocking-the-untapped-chemical-diversity-of-medicinal-341f859e1c659ac5PharmaRadar360en2026-09-19T00:00:00.000ZPhytochemical dark matter: unlocking the untapped chemical diversity of medicinal plantshttps://www.pharmaradar360.com/article/oroxylin-a-loaded-microemulsion-gel-a-promising-approach-for-anti-gout-therapy-a-7d7fc2b7ca4b7e5bPharmaRadar360en2026-09-19T00:00:00.000ZOroxylin A- loaded microemulsion gel: a promising approach for anti-gout therapy- a reviewhttps://www.pharmaradar360.com/article/plant-protein-microcapsules-for-nutraceutical-delivery-3b5fb647884c6359PharmaRadar360en2026-09-19T00:00:00.000ZPlant protein microcapsules for nutraceutical deliveryhttps://www.pharmaradar360.com/article/quality-control-evaluation-of-different-brands-of-paracetamol-tablets-available-c006a743158b4b8cPharmaRadar360en2026-09-19T00:00:00.000ZQuality control evaluation of different brands of paracetamol tablets available in the local market of Rohtakhttps://www.pharmaradar360.com/article/clinical-correlation-between-the-severity-of-periodontitis-and-alzheimer-s-disea-48dd87cd72f1219bPharmaRadar360en2026-09-19T00:00:00.000ZClinical correlation between the severity of periodontitis and Alzheimer’s disease, along with neuropsychiatric symptoms in the rural populationhttps://www.pharmaradar360.com/article/predicting-hemorrhagic-transformation-in-acute-ischemic-stroke-using-a-machine-l-38c2eae679ddb40bPharmaRadar360en2026-09-19T00:00:00.000ZPredicting hemorrhagic transformation in acute ischemic stroke using a machine learning model based on clinical and HR-MRI featureshttps://www.pharmaradar360.com/article/effects-of-adding-gait-retraining-with-visual-feedback-to-resistance-balance-tra-1e167cbe3a805226PharmaRadar360en2026-09-19T00:00:00.000ZEffects of adding gait retraining with visual feedback to resistance-balance training on kinematics, centers of pressure, and proprioception in individuals with chronic ankle instability: a randomized controlled trialhttps://www.pharmaradar360.com/article/low-intensity-transcranial-electrical-stimulation-for-schizophrenia-a-triple-bli-e89af31c21e6c675PharmaRadar360en2026-09-19T00:00:00.000ZLow intensity transcranial electrical stimulation for schizophrenia: a triple-blind, randomized, sham-controlled multicenter trial (STIM’Zo)https://www.pharmaradar360.com/article/clinical-indications-and-determinants-of-field-of-view-selection-in-cone-beam-co-502e081a3fdf5538PharmaRadar360en2026-09-19T00:00:00.000ZClinical indications and determinants of field-of-view selection in cone-beam computed tomography among pediatric patients: a two-center cross-sectional studyhttps://www.pharmaradar360.com/article/systemic-antibiotic-use-in-paediatric-odontogenic-infections-a-systematic-review-c467c59adf57184aPharmaRadar360en2026-09-19T00:00:00.000ZSystemic antibiotic use in paediatric odontogenic infections: a systematic review of clinical outcomes, prescribing practices, and guideline adherencehttps://www.pharmaradar360.com/article/asymmetrical-bilateral-ureteral-duplication-a-cadaveric-case-report-illustrating-c69d3b4b913c453cPharmaRadar360en2026-09-19T00:00:00.000ZAsymmetrical bilateral ureteral duplication: a cadaveric case report illustrating the clinical implications of a rare congenital urinary tract anomalyhttps://www.pharmaradar360.com/article/minimally-invasive-needle-arthroscopy-versus-conventional-arthroscopy-for-treatm-6fc5da0721eea615PharmaRadar360en2026-09-19T00:00:00.000ZMinimally invasive needle arthroscopy versus conventional arthroscopy for treatment of bacterial knee arthritis: protocol of a pragmatic, multicenter, randomized, controlled, non-inferiority trial (MINA-TRIAL)https://www.pharmaradar360.com/article/effects-of-companion-based-emotional-care-on-treatment-adherence-and-physiologic-51e959a4f87a7502PharmaRadar360en2026-09-19T00:00:00.000ZEffects of companion-based emotional care on treatment adherence and physiological-psychological outcomes in AECOPD patients with respiratory failure undergoing noninvasive ventilation: a randomized controlled trialhttps://www.pharmaradar360.com/article/self-medication-among-pharmacy-technician-students-in-offa-nigeria-implications-5a745c612e38bddcPharmaRadar360en2026-09-19T00:00:00.000ZSelf-medication among pharmacy technician students in Offa, Nigeria: implications for rational drug use and future healthcare practicehttps://www.pharmaradar360.com/article/school-based-hygiene-intervention-to-prevent-helicobacter-pylori-infection-among-fb3eeb7f9942f557PharmaRadar360en2026-09-19T00:00:00.000ZSchool-based hygiene intervention to prevent Helicobacter Pylori infection among children (SHIP HOPE): a cluster-randomized controlled trialhttps://www.pharmaradar360.com/article/evaluating-a-smartphone-intervention-to-improve-hiv-prevention-and-care-outcomes-bd52996327321260PharmaRadar360en2026-09-19T00:00:00.000ZEvaluating a smartphone intervention to improve HIV prevention and care outcomes: results from the HealthMPowerment national randomized controlled trialhttps://www.pharmaradar360.com/article/perceived-risk-of-cardiovascular-diseases-in-the-italian-population-a-baseline-c-1d63a7e202355d83PharmaRadar360en2026-09-19T00:00:00.000ZPerceived risk of cardiovascular diseases in the Italian population: a baseline cross-sectional analysis of participants enrolled in the INNOPREV trialhttps://www.pharmaradar360.com/article/efficacy-of-progressive-muscle-relaxation-training-in-post-traumatic-stress-diso-96a07acf7bd3c00aPharmaRadar360en2026-09-19T00:00:00.000ZEfficacy of progressive muscle relaxation training in post-traumatic stress disorder after the Kahramanmaraş earthquake: a randomized controlled trialhttps://www.pharmaradar360.com/article/potentially-inappropriate-medication-use-and-selected-drug-related-problems-amon-7b866e4c8c711bc1PharmaRadar360en2026-09-19T00:00:00.000ZPotentially inappropriate medication use and selected drug-related problems among older adults in Aseer Region, Saudi Arabia: a retrospective multicenter studyhttps://www.pharmaradar360.com/article/impact-of-concomitant-grade-i-degenerative-spondylolisthesis-on-clinical-and-rad-b3aa13f3b078fc7dPharmaRadar360en2026-09-19T00:00:00.000ZImpact of Concomitant Grade I Degenerative Spondylolisthesis on Clinical and Radiographic Outcomeshttps://www.pharmaradar360.com/article/giddy-up-can-we-reduce-dropouts-in-a-discrete-choice-experiment-by-including-an-19993b5edd03242dPharmaRadar360en2026-09-19T00:00:00.000ZGiddy up! Can We Reduce Dropouts in a Discrete-Choice Experiment by Including an Encouraging Message? A Randomised Trialhttps://www.pharmaradar360.com/article/partial-mock-up-guided-rehabilitation-of-severe-tooth-wear-a-clinical-technique-ff05853f0fa3d358PharmaRadar360en2026-09-19T00:00:00.000ZPartial Mock‐Up–Guided Rehabilitation of Severe Tooth Wear: A Clinical Techniquehttps://www.pharmaradar360.com/article/care-gaps-following-newly-detected-dipstick-proteinuria-in-treated-hypertension-f6038d0fa7cd35f9PharmaRadar360en2026-09-19T00:00:00.000ZCare Gaps Following Newly Detected Dipstick Proteinuria in Treated Hypertension: A Japanese Nationwide Database Studyhttps://www.pharmaradar360.com/article/systematic-benchmarking-of-evaluation-paradigms-safety-boundaries-and-clinical-r-b9d82694e09b72b9PharmaRadar360en2026-09-19T00:00:00.000ZSystematic benchmarking of evaluation paradigms, safety boundaries, and clinical reasoning gaps for multimodal large language models in rehabilitationhttps://www.pharmaradar360.com/article/thermodynamic-molecular-interdependencies-and-causal-determinants-governing-phar-10f10c771e7ee1bfPharmaRadar360en2026-09-19T00:00:00.000ZThermodynamic–molecular interdependencies and causal determinants governing pharmaceutical solubility in SC-CO2 systemshttps://www.pharmaradar360.com/article/integrating-hitop-and-clinical-staging-a-developmental-framework-for-multidimens-b476eea2461db944PharmaRadar360en2026-09-19T00:00:00.000ZIntegrating HiTOP and clinical staging: A developmental framework for multidimensional psychiatric assessmenthttps://www.pharmaradar360.com/article/long-term-clinical-outcomes-of-a-hydrofilic-extended-depth-of-focus-intraocular-e572e5d1e90d64cfPharmaRadar360en2026-09-19T00:00:00.000ZLong-Term Clinical Outcomes of a Hydrofilic Extended Depth-of-Focus Intraocular Lenshttps://www.pharmaradar360.com/article/the-impact-of-antihypertensive-de-escalation-a-secondary-analysis-of-systolic-bl-aa5240ab42a1ed19PharmaRadar360en2026-09-19T00:00:00.000ZThe Impact of Antihypertensive De-escalation: A Secondary Analysis of Systolic Blood Pressure Intervention Trial (SPRINT)https://www.pharmaradar360.com/article/sertraline-e9737e737cba8913PharmaRadar360en2026-09-19T00:00:00.000ZSertralinehttps://www.pharmaradar360.com/article/salicylates-50f1ce7783b22311PharmaRadar360en2026-09-19T00:00:00.000ZSalicylateshttps://www.pharmaradar360.com/article/nitrous-oxide-6c11750953e77a2ePharmaRadar360en2026-09-19T00:00:00.000ZNitrous oxidehttps://www.pharmaradar360.com/article/metamfetamine-123bf776ae9e5ebdPharmaRadar360en2026-09-19T00:00:00.000ZMetamfetaminehttps://www.pharmaradar360.com/article/lithium-paracetamol-d20337e1f8385dbePharmaRadar360en2026-09-19T00:00:00.000ZLithium/Paracetamolhttps://www.pharmaradar360.com/article/dicycloverine-0773d3ef428c7525PharmaRadar360en2026-09-19T00:00:00.000ZDicycloverinehttps://www.pharmaradar360.com/article/diamorphine-95e6194fbd91bf71PharmaRadar360en2026-09-19T00:00:00.000ZDiamorphinehttps://www.pharmaradar360.com/article/daptomycin-3c236bfd74a7ae7ePharmaRadar360en2026-09-19T00:00:00.000ZDaptomycinhttps://www.pharmaradar360.com/article/amlodipine-propranolol-fa0af215e5fdd4edPharmaRadar360en2026-09-19T00:00:00.000ZAmlodipine/Propranololhttps://www.pharmaradar360.com/article/deciphering-the-interaction-landscape-of-ndm-1-with-a-novel-lactam-based-inhibit-50512220ed8c509dPharmaRadar360en2026-09-19T00:00:00.000ZDeciphering the interaction landscape of NDM-1 with a novel β-lactam-based inhibitor: implications for rational drug designhttps://www.pharmaradar360.com/article/piper-betle-essential-oil-enhances-antibiotic-susceptibility-and-attenuates-quor-de37c35cede42ef5PharmaRadar360en2026-09-19T00:00:00.000ZPiper betle essential oil enhances antibiotic susceptibility and attenuates quorum-sensing-associated virulence in Staphylococcus aureus in vitrohttps://www.pharmaradar360.com/article/effectiveness-of-a-card-game-based-intervention-in-alleviating-preoperative-anxi-15dbe051b2ff20baPharmaRadar360en2026-09-19T00:00:00.000ZEffectiveness of a card game-based intervention in alleviating preoperative anxiety in children: a randomized controlled trialhttps://www.pharmaradar360.com/article/micellar-systems-with-hydrophobic-core-stabilized-polyethyleneimine-enabling-tim-687784dcfb17eba7PharmaRadar360en2026-09-19T00:00:00.000ZMicellar Systems with Hydrophobic Core-Stabilized Polyethyleneimine Enabling Time-Dependent Positive Zeta Potential Transformation for Enhanced Intestinal Mucopermeation and Cellular Uptakehttps://www.pharmaradar360.com/article/ai-based-smoke-removal-in-robotic-urooncologic-surgery-a-clinical-pilot-study-4053782a128a77b3PharmaRadar360en2026-09-19T00:00:00.000ZAI-based smoke removal in robotic urooncologic surgery: a clinical pilot studyhttps://www.pharmaradar360.com/article/conceptual-growth-curves-of-oropharyngeal-soft-tissues-and-craniofacial-skeletal-d450161164c51a8cPharmaRadar360en2026-09-19T00:00:00.000ZConceptual growth curves of oropharyngeal soft tissues and craniofacial skeletal structures: clinical implications for pediatric airway managementhttps://www.pharmaradar360.com/article/brief-cognitive-behavioral-therapy-for-suicide-prevention-among-racially-and-eth-0036a6580553d84cPharmaRadar360en2026-09-19T00:00:00.000ZBrief Cognitive-Behavioral Therapy for Suicide Prevention Among Racially and Ethnically Minoritized Soldiers: A Secondary Analysis of a Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nature-based-interventions-in-practice-a-scoping-review-of-social-work-literatur-37b90182012c11fcPharmaRadar360en2026-09-19T00:00:00.000ZNature-Based Interventions in Practice: A Scoping Review of Social Work Literaturehttps://www.pharmaradar360.com/article/systematic-review-and-network-meta-analysis-for-the-2026-update-of-the-evidence-a7b29411b4772e4dPharmaRadar360en2026-09-19T00:00:00.000ZSystematic review and network meta-analysis for the 2026 update of the evidence-based clinical practice guidelines for the management with immunosuppressive therapies and biologic agents of membranous nephropathyhttps://www.pharmaradar360.com/article/adverse-event-risks-and-prognostic-factors-associated-with-endoscopic-laryngopha-70d33963692fe251PharmaRadar360en2026-09-19T00:00:00.000ZAdverse event risks and prognostic factors associated with endoscopic laryngopharyngeal surgery for superficial head and neck cancer after chemoradiotherapyhttps://www.pharmaradar360.com/article/effectiveness-of-low-level-laser-therapy-in-the-rehabilitation-of-knee-meniscus-d2ca201f02c9cb87PharmaRadar360en2026-09-19T00:00:00.000ZEffectiveness of low-level laser therapy in the rehabilitation of knee meniscus injuries: a randomized, double-blind, placebo-controlled trialhttps://www.pharmaradar360.com/article/the-microvascular-footprint-of-lupus-nailfold-capillaroscopy-findings-in-egyptia-9a72384817265498PharmaRadar360en2026-09-19T00:00:00.000ZThe microvascular footprint of lupus: nailfold capillaroscopy findings in Egyptian SLE patients and their link to disease activity, autoantibodies, and digital ischemiahttps://www.pharmaradar360.com/article/integration-of-early-palliative-care-in-cancer-treatment-a-meta-analysis-of-39-r-2e2b33d95289c590PharmaRadar360en2026-09-19T00:00:00.000ZIntegration of early palliative care in cancer treatment: a meta-analysis of 39 randomized controlled trials on clinical outcomes and management optimizationhttps://www.pharmaradar360.com/article/outcomes-of-surgical-intervention-in-retinal-detachment-in-stickler-syndrome-a-s-d4130766d2a7171bPharmaRadar360en2026-09-19T00:00:00.000ZOutcomes of surgical intervention in retinal detachment in stickler syndrome: a systematic review and meta analysishttps://www.pharmaradar360.com/article/analysis-of-brain-volumetry-and-functional-connectivity-during-resting-state-in-eb430aad5af9a35ePharmaRadar360en2026-09-19T00:00:00.000ZAnalysis of brain volumetry and functional connectivity during resting state in patients with borderline personality disorderhttps://www.pharmaradar360.com/article/accelerated-tms-is-associated-with-changes-of-subgenual-cingulate-default-mode-n-8dc272ce8dd99d43PharmaRadar360en2026-09-19T00:00:00.000ZAccelerated TMS is associated with changes of subgenual cingulate–default mode network coupling in depression: an observational 7 Tesla fMRI studyhttps://www.pharmaradar360.com/article/case-based-pharmacotherapeutic-learning-structured-around-the-prescribing-optimi-58d9c0cc03a64972PharmaRadar360en2026-09-19T00:00:00.000ZCase-based pharmacotherapeutic learning structured around the prescribing optimization method and the WHO 6-step model: Medical students’ views from an exploratory questionnaire studyhttps://www.pharmaradar360.com/article/genetically-supported-targets-and-drug-repurposing-for-sleep-disorders-a-mendeli-996bda825dee064aPharmaRadar360en2026-09-19T00:00:00.000ZGenetically supported targets and drug repurposing for sleep disorders: a Mendelian randomization systematic studyhttps://www.pharmaradar360.com/article/from-diagnostic-accuracy-to-clinical-utility-methodological-considerations-on-co-9df4003c012e3774PharmaRadar360en2026-09-19T00:00:00.000ZFrom Diagnostic Accuracy to Clinical Utility: Methodological Considerations on Contrast‐Enhanced Ultrasono‐Distal Cologram in Anorectal Malformationshttps://www.pharmaradar360.com/article/effects-of-continuing-or-withholding-angiotensin-axis-blockers-prior-to-elective-595c845626078b7cPharmaRadar360en2026-09-19T00:00:00.000ZEffects of continuing or withholding angiotensin axis blockers prior to elective surgery: The PAAB randomized clinical trialhttps://www.pharmaradar360.com/article/operationalization-of-the-african-medicines-agency-retrospective-evaluation-of-t-159de1ff28a10a52PharmaRadar360en2026-09-19T00:00:00.000ZOperationalization of the African Medicines Agency: Retrospective evaluation of the continental centralized pilot procedure timelines to recommendation and national registrationshttps://www.pharmaradar360.com/article/retension-pharmaceuticals-trex-bio-file-for-us-ipo-as-biotech-momentum-continues-2f48405acfbfdc68PharmaRadar360en2026-09-18T23:59:53.000ZRetension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continueshttps://www.pharmaradar360.com/article/hoth-s-pivot-from-biotech-to-space-tech-sparks-massive-rally-in-stock-retail-und-fea1a8d486dec34bPharmaRadar360en2026-09-18T23:43:59.000ZHOTH’s Pivot From Biotech To Space Tech Sparks Massive Rally In Stock – Retail Underlines Importance Of Securing Fresh Dealshttps://www.pharmaradar360.com/article/anthropic-is-operating-a-lab-that-conducts-biology-experiments-c2a67f2be86581adPharmaRadar360en2026-09-18T23:13:31.000ZAnthropic is operating a lab that conducts biology experimentshttps://www.pharmaradar360.com/article/analysts-think-axsome-therapeutics-stock-could-soar-35-over-the-next-12-months-i-e56809726c192c50PharmaRadar360en2026-09-18T23:02:00.000ZAnalysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?https://www.pharmaradar360.com/article/omnideployment-the-future-of-pharmaceutical-commercialization-1f60f5db440b5bd7PharmaRadar360en2026-09-18T22:53:20.000ZOmnideployment: The Future of Pharmaceutical Commercializationhttps://www.pharmaradar360.com/article/analysts-think-axsome-therapeutics-stock-could-soar-35-over-the-next-12-months-i-4d1ca8ecf7dd9852PharmaRadar360en2026-09-18T22:38:41.000ZAnalysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?https://www.pharmaradar360.com/article/retension-pharmaceuticals-trex-bio-file-for-us-ipo-as-biotech-momentum-continues-9706597300d79daaPharmaRadar360en2026-09-18T22:35:17.000ZRetension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continueshttps://www.pharmaradar360.com/article/the-specter-of-ai-enabled-bioweapons-is-a-wake-up-call-for-biotech-1e7372ba15a5f576PharmaRadar360en2026-09-18T22:28:22.000ZThe specter of AI-enabled bioweapons is a wake-up call for biotechhttps://www.pharmaradar360.com/article/fda-examines-use-of-testosterone-prescriptions-for-menopause-c359720bb3a5c490PharmaRadar360en2026-09-18T22:26:23.000ZFDA examines use of testosterone prescriptions for menopausehttps://www.pharmaradar360.com/article/analysts-think-axsome-therapeutics-stock-could-soar-35-over-the-next-12-months-i-028baa1e5af406d9PharmaRadar360en2026-09-18T22:22:30.000ZAnalysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?https://www.pharmaradar360.com/article/virtual-biotech-company-puts-37-000-ai-agents-to-work-on-drug-discovery-0ab60bbf89b1de5ePharmaRadar360en2026-09-18T22:11:54.000ZVirtual Biotech Company Puts 37,000 AI Agents to Work on Drug Discoveryhttps://www.pharmaradar360.com/article/consulta-publica-requerimientos-tecnicos-administrativos-cb077950f600650aPharmaRadar360en2026-09-18T21:42:36.000ZCONSULTA PÚBLICA REQUERIMIENTOS TÉCNICOS ADMINISTRATIVOShttps://www.pharmaradar360.com/article/trxb-ipo-news-autoimmune-and-inflammatory-diseases-biotech-trex-bio-files-for-a-f91025b93b89cfb7PharmaRadar360en2026-09-18T21:39:00.000ZTRXB IPO News - Autoimmune and inflammatory diseases biotech TRex Bio files for a $100 million IPOhttps://www.pharmaradar360.com/article/mizuho-s-jared-holz-data-doesn-t-show-a-strong-link-between-biotech-and-interest-55a37aa704a9bd07PharmaRadar360en2026-09-18T21:38:00.000ZMizuho's Jared Holz: Data doesn't show a strong link between biotech and interest rateshttps://www.pharmaradar360.com/article/high-throughput-aav-affinity-chromatography-screening-99009d14e786d1a1PharmaRadar360en2026-09-18T21:27:20.000ZHigh-Throughput AAV Affinity Chromatography Screeninghttps://www.pharmaradar360.com/article/mirum-pharmaceuticals-falls-7-1-as-investors-appear-to-reassess-near-term-biotec-1d2cd1c93d265677PharmaRadar360en2026-09-18T21:20:00.000ZMirum Pharmaceuticals Falls 7.1% as Investors Appear to Reassess Near-Term Biotech Catalystshttps://www.pharmaradar360.com/article/white-house-extends-mfn-pricing-to-every-state-medicaid-program-46597a1d0cb97779PharmaRadar360en2026-09-18T21:19:08.000ZWhite House Extends MFN Pricing to Every State Medicaid Programhttps://www.pharmaradar360.com/article/retension-pharmaceuticals-clinical-stage-biopharma-for-hypertension-files-for-na-500bd9025ece2e61PharmaRadar360en2026-09-18T21:18:05.000ZRetension Pharmaceuticals, Clinical-Stage Biopharma for Hypertension, Files for Nasdaq Capital Market IPOhttps://www.pharmaradar360.com/article/moleculin-biotech-disclosed-failure-to-satisfy-a-continued-listing-rule-or-stand-e8243697e82aa9a0PharmaRadar360en2026-09-18T21:03:04.000ZMoleculin Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standardhttps://www.pharmaradar360.com/article/investment-fund-tied-to-teva-nyse-teva-director-plans-share-sale-2f066a6ddabc3077PharmaRadar360en2026-09-18T21:00:58.000ZInvestment fund tied to Teva (NYSE: TEVA) director plans share salehttps://www.pharmaradar360.com/article/lakewood-amedex-announces-irb-approval-to-initiate-phase-2a-clinical-trial-of-nu-eb20b4f8617ed6baPharmaRadar360en2026-09-18T20:59:00.000ZLakewood-Amedex Announces IRB Approval to Initiate Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcershttps://www.pharmaradar360.com/article/fda-launches-pilot-program-to-speed-early-clinical-trials-e9db1ce137d303a4PharmaRadar360en2026-09-18T20:52:52.000ZFDA Launches Pilot Program to Speed Early Clinical Trialshttps://www.pharmaradar360.com/article/fda-approves-fayuvi-pharmexec-a23663528c3d4358PharmaRadar360en2026-09-18T20:45:47.000ZFDA Approves Fayuvi | PharmExechttps://www.pharmaradar360.com/article/saved-by-wife-s-cpr-bay-area-survivor-leads-heart-walk-to-build-nation-of-lifesa-ec36780d62d0d2bdPharmaRadar360en2026-09-18T20:43:00.000ZSaved by Wife’s CPR, Bay Area Survivor Leads Heart Walk to Build Nation of Lifesavershttps://www.pharmaradar360.com/article/the-biotech-ipo-window-keeps-opening-09264c228e834eaePharmaRadar360en2026-09-18T20:23:46.000ZThe biotech IPO window keeps openinghttps://www.pharmaradar360.com/article/why-this-biotech-just-erased-its-one-day-50-pop-69c3a9008e5f3dadPharmaRadar360en2026-09-18T20:08:00.000ZWhy This Biotech Just Erased Its One-Day 50% Pophttps://www.pharmaradar360.com/article/amneal-announces-fda-approval-and-launch-of-lanreotide-injection-717b592a47d5528fPharmaRadar360en2026-09-18T20:01:00.000ZAmneal Announces FDA Approval and Launch of Lanreotide Injectionhttps://www.pharmaradar360.com/article/novo-nordisk-taps-anthropic-s-claude-to-speed-drug-discovery-6bb9050bfd33342bPharmaRadar360en2026-09-18T19:57:47.000ZNovo Nordisk taps Anthropic's Claude to speed drug discoveryhttps://www.pharmaradar360.com/article/trump-to-announce-all-50-states-joining-medicaid-drug-pricing-model-7e1e4bb1b9a04278PharmaRadar360en2026-09-18T19:46:39.000ZTrump to announce all 50 states joining Medicaid drug pricing modelhttps://www.pharmaradar360.com/article/trump-to-announce-all-50-states-joining-medicaid-drug-pricing-model-843f8dad1754e2e8PharmaRadar360en2026-09-18T19:41:54.000ZTrump to announce all 50 states joining Medicaid drug pricing modelhttps://www.pharmaradar360.com/article/vantuil-pereira-e-reconduzido-a-decania-do-centro-de-filosofia-e-ciencias-humana-b4aa1e29c3408934PharmaRadar360en2026-09-18T19:38:00.000ZVantuil Pereira é reconduzido à decania do Centro de Filosofia e Ciências Humanashttps://www.pharmaradar360.com/article/ai-may-kill-us-all-but-biotech-is-the-bigger-threat-to-stocks-cabot-street-check-f6aae46ec1c2910cPharmaRadar360en2026-09-18T19:36:51.000ZAI May Kill Us All. But Biotech Is the Bigger Threat to Stocks | Cabot Street Checkhttps://www.pharmaradar360.com/article/veraxa-biotech-vrxa-adds-capital-markets-veteran-as-cfo-while-advancing-bitac-on-a0783c107c82669cPharmaRadar360en2026-09-18T19:30:00.000ZVERAXA Biotech (VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipelinehttps://www.pharmaradar360.com/article/steve-marshall-offers-warning-to-rubio-about-chinese-national-security-threat-in-f029735522effd19PharmaRadar360en2026-09-18T19:05:48.000ZSteve Marshall offers warning to Rubio about Chinese ‘national security threat’ in pharmaceutical supply chainhttps://www.pharmaradar360.com/article/china-plans-to-transform-3m-biotech-sector-into-522b-powerhouse-by-2030-f0565aa05697d5e2PharmaRadar360en2026-09-18T19:05:42.000ZChina plans to transform $3M biotech sector into $522B powerhouse by 2030https://www.pharmaradar360.com/article/xenon-stock-craters-30-on-drug-trial-setback-its-failure-could-be-this-biotech-s-56a2fa84d3bb02c3PharmaRadar360en2026-09-18T18:55:21.000ZXenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.https://www.pharmaradar360.com/article/insilico-medicine-sehk-3696-advances-rentosertib-into-phase-3-trials-df912cbea33fd048PharmaRadar360en2026-09-18T18:45:19.000ZInSilico Medicine (SEHK:3696) Advances Rentosertib Into Phase 3 Trialshttps://www.pharmaradar360.com/article/fda-issues-food-safety-advisory-for-ganpati-mahaprasad-5cb211e0958c2affPharmaRadar360en2026-09-18T18:42:00.000ZFDA Issues Food Safety Advisory For Ganpati Mahaprasadhttps://www.pharmaradar360.com/article/fda-seizes-593kg-expired-ghee-in-akola-12d85b5806ed4aa9PharmaRadar360en2026-09-18T18:38:00.000ZFDA seizes 593kg expired ghee in Akolahttps://www.pharmaradar360.com/article/cordis-project-personalised-medicine-by-using-an-advanced-point-of-care-tool-for-8b4326c6c0ba25ccPharmaRadar360en2026-09-18T18:26:51.000ZCORDIS project: Personalised Medicine by using an Advanced Point-of-Care Tool for Stratified Treatment in High Risk Cardiovascular Patients (PoCCardio)https://www.pharmaradar360.com/article/cordis-project-future-of-alcl-novel-therapies-origins-bio-markers-and-mechanism-27cd89b4f8f7af8cPharmaRadar360en2026-09-18T18:26:38.000ZCORDIS project: Future of ALCL: Novel Therapies, Origins, Bio-Markers and Mechanism of resistancehttps://www.pharmaradar360.com/article/cordis-project-reducing-the-impact-of-major-environmental-challenges-on-mental-h-31bc826d56d240c6PharmaRadar360en2026-09-18T18:26:31.000ZCORDIS project: Reducing the impact of major environmental challenges on mental healthhttps://www.pharmaradar360.com/article/cordis-project-transforming-into-a-sustainable-european-pharmaceutical-sector-28dd3912c72b3695PharmaRadar360en2026-09-18T18:26:30.000ZCORDIS project: Transforming into a sustainable European pharmaceutical sectorhttps://www.pharmaradar360.com/article/cordis-project-understanding-predicting-and-treating-depression-in-pregnancy-to-3a9a37311258eec2PharmaRadar360en2026-09-18T18:26:29.000ZCORDIS project: Understanding, predicting, and treating depression in pregnancy to improve mothers and offspring mental health outcomeshttps://www.pharmaradar360.com/article/xene-stock-drops-30-on-phase-3-trial-halt-price-to-sales-ratio-signals-market-sk-7c05d70fbabc3156PharmaRadar360en2026-09-18T18:25:38.000ZXENE Stock Drops 30% on Phase 3 Trial Halt; Price-to-Sales Ratio Signals Market Skepticismhttps://www.pharmaradar360.com/article/genmab-stock-gains-as-petosemtamab-phase-3-start-and-strong-q2-figures-support-v-c1aa15b564b629fcPharmaRadar360en2026-09-18T18:20:44.000ZGenmab stock gains as petosemtamab Phase 3 start and strong Q2 figures support valuationhttps://www.pharmaradar360.com/article/veraxa-biotech-nasdaq-vrxa-appoints-raju-willener-as-cfo-9709b95d0f9b3358PharmaRadar360en2026-09-18T18:03:52.000ZVERAXA Biotech (NASDAQ:VRXA) Appoints Raju Willener as CFOhttps://www.pharmaradar360.com/article/is-this-biotech-stock-too-cheap-to-ignore-after-its-latest-pullback-91f5f5b430dc71f5PharmaRadar360en2026-09-18T18:00:00.000ZIs This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?https://www.pharmaradar360.com/article/first-drug-to-treat-alexander-disease-approved-by-the-fda-after-three-decades-of-34a9482c55fea16cPharmaRadar360en2026-09-18T17:55:04.000ZFirst drug to treat Alexander disease approved by the FDA after three decades of research at UW–Madisonhttps://www.pharmaradar360.com/article/is-legend-biotech-legn-undervalued-following-its-new-ceo-appointment-066eb92b1b6f57caPharmaRadar360en2026-09-18T17:53:33.000ZIs Legend Biotech (LEGN) Undervalued Following Its New CEO Appointment?https://www.pharmaradar360.com/article/sahpra-reinforces-its-commitment-to-radiation-safety-at-iaea-general-conference-1042c5a1d277999bPharmaRadar360en2026-09-18T17:32:15.000ZSAHPRA Reinforces Its Commitment to Radiation Safety at IAEA General Conferencehttps://www.pharmaradar360.com/article/is-legend-biotech-legn-undervalued-following-its-new-ceo-appointment-a9f1a69f6fd68a4ePharmaRadar360en2026-09-18T17:30:52.000ZIs Legend Biotech (LEGN) Undervalued Following Its New CEO Appointment?https://www.pharmaradar360.com/article/is-this-biotech-stock-too-cheap-to-ignore-after-its-latest-pullback-8a72dc88fe000b4ePharmaRadar360en2026-09-18T17:20:00.000ZIs This Biotech Stock Too Cheap to Ignore After Its Latest Pullback?https://www.pharmaradar360.com/article/beyond-clinical-endpoints-rethinking-als-drug-development-through-disease-biolog-b7cd7818b37e9411PharmaRadar360en2026-09-18T17:15:54.000ZBeyond clinical endpoints: Rethinking ALS drug development through disease biologyhttps://www.pharmaradar360.com/article/montana-opened-a-market-for-experimental-medicines-now-it-should-watch-who-shows-b84ace46a9df7e13PharmaRadar360en2026-09-18T17:14:13.000ZMontana opened a market for experimental medicines. Now it should watch who shows uphttps://www.pharmaradar360.com/article/pune-fda-seizes-adulterated-food-worth-rs-56-36-lakh-banned-gutkha-worth-rs-20-2-b25b754ddcb9cba2PharmaRadar360en2026-09-18T17:08:24.000ZPune FDA Seizes Adulterated Food Worth Rs 56.36 Lakh, Banned Gutkha Worth Rs 20.26 Lakh in Festive Drivehttps://www.pharmaradar360.com/article/post-hoc-live-the-china-biotech-debate-goes-to-washington-601b5ca4af133974PharmaRadar360en2026-09-18T17:08:00.000ZPost-Hoc Live: The China Biotech Debate goes to Washingtonhttps://www.pharmaradar360.com/article/agriculture-studies-networks-for-food-security-agri-net-jica-c3fe72a28b1dd90dPharmaRadar360en2026-09-18T17:04:39.000ZAgriculture Studies Networks for Food Security (Agri-Net) – JICAhttps://www.pharmaradar360.com/article/exclusive-us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say-d48516f28aaf5220PharmaRadar360en2026-09-18T16:54:37.000ZEXCLUSIVE: US weighs allowing most pharma licensing deals with China, sources sayhttps://www.pharmaradar360.com/article/radar-st-84ce3e802a2d1e73PharmaRadar360en2026-09-18T16:52:59.000ZRaDaR® SThttps://www.pharmaradar360.com/article/umd-students-band-together-to-protect-birds-b1696d7be266e817PharmaRadar360en2026-09-18T16:50:32.000ZUMD students band together to protect birdshttps://www.pharmaradar360.com/article/big-lake-agrivoltaics-project-shows-promise-of-mixing-farming-solar-power-e943f5608c414bf6PharmaRadar360en2026-09-18T16:50:01.000ZBig Lake agrivoltaics project shows promise of mixing farming, solar powerhttps://www.pharmaradar360.com/article/umd-engineers-building-brighter-futures-from-duluth-to-kenya-5875172bba4f6965PharmaRadar360en2026-09-18T16:49:16.000ZUMD Engineers building brighter futures from Duluth to Kenyahttps://www.pharmaradar360.com/article/hornets-are-sending-minnesotans-to-the-er-and-into-party-mode-3a7c2094446f40fcPharmaRadar360en2026-09-18T16:48:57.000ZHornets are sending Minnesotans to the ER — and into party modehttps://www.pharmaradar360.com/article/trump-s-authoritarian-mindset-can-t-handle-dissent-from-his-appointees-0f72e70f2f17c74bPharmaRadar360en2026-09-18T16:48:38.000ZTrump’s authoritarian mindset can’t handle dissent from his appointeeshttps://www.pharmaradar360.com/article/glass-pumpkin-patch-at-the-arboretum-d02dfdd728c01c10PharmaRadar360en2026-09-18T16:48:06.000ZGlass Pumpkin Patch at the Arboretumhttps://www.pharmaradar360.com/article/can-ai-agents-satisfy-cgmp-documentation-requirements-609a4915047af303PharmaRadar360en2026-09-18T16:35:47.000ZCan AI Agents Satisfy CGMP Documentation Requirements?https://www.pharmaradar360.com/article/dallas-clinical-research-unit-sponsor-overview-f49234afe6268753PharmaRadar360en2026-09-18T16:33:15.000ZDallas Clinical Research Unit: Sponsor overviewhttps://www.pharmaradar360.com/article/4-biotech-stocks-to-watch-as-potential-takeover-targets-471a060d652d759aPharmaRadar360en2026-09-18T16:31:00.000Z4 Biotech Stocks to Watch as Potential Takeover Targetshttps://www.pharmaradar360.com/article/when-ev-dose-is-not-what-it-seems-quantitative-mismatch-between-particle-number-f47a7c5a1a3284b4PharmaRadar360en2026-09-18T16:29:38.000ZWhen EV Dose Is Not What It Seems: Quantitative Mismatch Between Particle Number- and Protein-Based Dosinghttps://www.pharmaradar360.com/article/a-false-attack-on-vivek-ramaswamy-raises-a-harder-question-who-hears-the-correct-740dd3f761e3a48cPharmaRadar360en2026-09-18T16:17:00.000ZA false attack on Vivek Ramaswamy raises a harder question: Who hears the correction?https://www.pharmaradar360.com/article/semi-mechanistic-joint-population-pharmacokinetic-modeling-of-the-novel-antitube-ebec18c2810c96c6PharmaRadar360en2026-09-18T16:02:31.000ZSemi-Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteershttps://www.pharmaradar360.com/article/mabxience-sandoz-partner-on-emicizumab-biosimilar-deal-a640a1a39a3338f8PharmaRadar360en2026-09-18T15:56:19.000ZmAbxience, Sandoz Partner on Emicizumab Biosimilar Dealhttps://www.pharmaradar360.com/article/frazier-life-sciences-adds-1-1b-to-biotech-fund-84639908b0e2b140PharmaRadar360en2026-09-18T15:50:57.000ZFrazier Life Sciences Adds $1.1B to Biotech Fundhttps://www.pharmaradar360.com/article/biotech-options-buzz-uthr-nmra-ewtx-904141373556fd38PharmaRadar360en2026-09-18T15:46:04.000ZBiotech Options Buzz: UTHR, NMRA, EWTXhttps://www.pharmaradar360.com/article/all-50-states-sign-up-for-trump-s-medicaid-most-favored-nation-plan-770767e418ae8a3aPharmaRadar360en2026-09-18T15:41:51.000ZAll 50 states sign up for Trump’s Medicaid most-favored-nation planhttps://www.pharmaradar360.com/article/do-you-have-to-be-bilingual-to-participate-in-circle-u-activities-c8b706a758c482a8PharmaRadar360en2026-09-18T15:39:27.000ZDo you have to be bilingual to participate in Circle U. activitieshttps://www.pharmaradar360.com/article/roche-expands-its-boston-footprint-with-new-research-center-61c8eaa9d2c59da9PharmaRadar360en2026-09-18T15:33:37.000ZRoche expands its Boston footprint with new research centerhttps://www.pharmaradar360.com/article/definium-trial-suggests-lsd-could-help-treat-anxiety-one-patient-meets-god-the-o-cb4c52a47721d100PharmaRadar360en2026-09-18T15:30:35.000ZDefinium trial suggests LSD could help treat anxiety; “One patient meets God. The other gets itchy.”; and Compass funds psilocybin-assisted therapist traininghttps://www.pharmaradar360.com/article/emirates-biotech-and-partner-launch-uae-organic-waste-to-biogas-pilot-7528d116c86d5b63PharmaRadar360en2026-09-18T15:24:56.000ZEmirates Biotech and partner launch UAE organic waste-to-biogas pilothttps://www.pharmaradar360.com/article/refreshed-novo-corrals-3-new-early-stage-obesity-drugs-from-kallyope-40f3fb0496b9f73ePharmaRadar360en2026-09-18T15:23:00.000ZRefreshed Novo corrals 3 new early-stage obesity drugs from Kallyopehttps://www.pharmaradar360.com/article/how-circle-u-helped-me-define-my-career-path-81b7d487eea3e910PharmaRadar360en2026-09-18T15:21:13.000ZHow Circle U. helped me define my career pathhttps://www.pharmaradar360.com/article/this-week-in-charts-gsk-s-china-deals-the-300m-ipo-club-and-selling-the-news-136aee8ad04163b2PharmaRadar360en2026-09-18T15:17:47.000ZThis week in charts: GSK’s China deals, the $300M IPO club and selling the newshttps://www.pharmaradar360.com/article/xenon-stock-reaction-is-overblown-analyst-00ea9c26fd548a87PharmaRadar360en2026-09-18T15:14:31.000ZXenon Stock Reaction Is Overblown: Analysthttps://www.pharmaradar360.com/article/cordis-project-metabolic-disease-heterogeneity-definition-prevention-and-remissi-02382b733dd4e87cPharmaRadar360en2026-09-18T15:12:02.000ZCORDIS project: Metabolic disease heterogeneity definition, prevention and remission with targeted interventionshttps://www.pharmaradar360.com/article/cordis-project-next-generation-therapeutics-for-vascular-diseases-3a4c8847c4d7458ePharmaRadar360en2026-09-18T15:11:56.000ZCORDIS project: Next-generation therapeutics for vascular diseaseshttps://www.pharmaradar360.com/article/addressing-the-treatment-gap-in-cannabis-use-disorder-ad222fb9336b9389PharmaRadar360en2026-09-18T15:09:43.000ZAddressing the Treatment Gap in Cannabis Use Disorderhttps://www.pharmaradar360.com/article/novartis-receives-positive-chmp-opinion-for-cosentyx-in-polymyalgia-rheumatica-p-72f0f6aa86cf0f0bPharmaRadar360en2026-09-18T15:04:43.000ZNovartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)https://www.pharmaradar360.com/article/how-ai-biotech-and-personalization-are-reshaping-the-beauty-industry-by-2030-932bc402d6e4135fPharmaRadar360en2026-09-18T15:04:37.000ZHow AI, biotech and personalization are reshaping the beauty industry by 2030https://www.pharmaradar360.com/article/european-adrs-slip-in-us-trading-as-biotech-splits-5d79b846c95a7a75PharmaRadar360en2026-09-18T15:00:13.000ZEuropean ADRs Slip In US Trading As Biotech Splitshttps://www.pharmaradar360.com/article/37-000-ai-agents-are-running-a-virtual-biotech-at-stanford-486a0da87125e24aPharmaRadar360en2026-09-18T14:52:51.000Z37,000 AI Agents Are Running a Virtual Biotech at Stanfordhttps://www.pharmaradar360.com/article/weekly-buzz-rare-bayry-win-approvals-sion-cuts-jobs-gsk-deals-azn-rhhby-lead-6f672e18822611c2PharmaRadar360en2026-09-18T14:44:00.000ZWeekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Leadhttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-sees-large-volume-increase-after-analyst-u-02e90aaa7ef82c7cPharmaRadar360en2026-09-18T14:42:34.000ZUltragenyx Pharmaceutical (NASDAQ:RARE) Sees Large Volume Increase After Analyst Upgradehttps://www.pharmaradar360.com/article/how-rebate-timing-distorts-a-pharmacy-s-340b-books-3fc20171d90a422cPharmaRadar360en2026-09-18T14:41:40.000ZHow Rebate Timing Distorts a Pharmacy's 340B Bookshttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-nasdaq-rare-price-target-raised-to-32-00-e4b617ea41d02a41PharmaRadar360en2026-09-18T14:38:33.000ZUltragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $32.00https://www.pharmaradar360.com/article/guidance-covid-19-test-validation-approved-products-8740f36d3b2718d0PharmaRadar360en2026-09-18T14:38:10.000ZGuidance: COVID-19 test validation approved productshttps://www.pharmaradar360.com/article/biotech-catalyst-stocks-with-binary-events-coming-up-0e77c7de51362b23PharmaRadar360en2026-09-18T14:36:13.000ZBiotech catalyst stocks with binary events coming uphttps://www.pharmaradar360.com/article/fda-approves-first-gene-therapy-for-sanfilippo-syndrome-type-a-ddacc8fe3f2a7e07PharmaRadar360en2026-09-18T14:32:42.000ZFDA approves first gene therapy for Sanfilippo syndrome type Ahttps://www.pharmaradar360.com/article/spn-exclusive-an-early-look-at-mcc-s-completed-3-million-biotech-lab-68ba636d342ac5cfPharmaRadar360en2026-09-18T14:30:00.000ZSPN Exclusive: An early look at MCC’s completed $3 million biotech labhttps://www.pharmaradar360.com/article/fda-approves-pixclara-first-fet-pet-agent-for-glioma-imaging-29a803462ba6b015PharmaRadar360en2026-09-18T14:30:00.000ZFDA Approves Pixclara, First FET-PET Agent for Glioma Imaginghttps://www.pharmaradar360.com/article/q-a-how-can-sponsors-respond-to-clinical-trial-customs-delays-6f1b84efeb049467PharmaRadar360en2026-09-18T14:24:16.000ZQ&A: How Can Sponsors Respond to Clinical Trial Customs Delays?https://www.pharmaradar360.com/article/ufrj-debate-defesa-da-democracia-confrontos-e-estrategias-de-comunicacao-em-reun-9eb7532f7d41d72aPharmaRadar360en2026-09-18T14:23:57.000ZUFRJ debate defesa da democracia, confrontos e estratégias de comunicação em reunião com professores eméritoshttps://www.pharmaradar360.com/article/fierce-pharma-asia-china-deals-safe-from-coins-key-wclc-data-legend-s-new-ceo-c23fdc3b607774daPharmaRadar360en2026-09-18T14:20:52.000ZFierce Pharma Asia—China deals safe from COINS?; Key WCLC data; Legend’s new CEOhttps://www.pharmaradar360.com/article/introducing-the-pharmtech-ai-pulse-check-expert-video-series-c9a61784abb684dePharmaRadar360en2026-09-18T14:20:07.000ZIntroducing the "PharmTech AI Pulse Check" Expert Video Serieshttps://www.pharmaradar360.com/article/aard-investor-alert-aardvark-therapeutics-inc-securities-class-action-notice-con-b0fff291ba5a6cc1PharmaRadar360en2026-09-18T14:09:00.000ZAARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinskyhttps://www.pharmaradar360.com/article/nordic-perspectives-on-education-a-two-book-launch-335960b186ef8c7dPharmaRadar360en2026-09-18T14:06:32.000ZNordic Perspectives on Education: A Two-Book Launchhttps://www.pharmaradar360.com/article/virtual-biotech-ai-system-advances-drug-discovery-with-37-000-agents-6df6d3ca1fbffbc8PharmaRadar360en2026-09-18T14:01:42.000ZVirtual Biotech AI System Advances Drug Discovery with 37,000 Agentshttps://www.pharmaradar360.com/article/a-closer-look-at-the-50-billion-rural-health-transformation-program-76a13771919bcee8PharmaRadar360en2026-09-18T14:00:00.000ZA Closer Look at the $50 Billion Rural Health Transformation Programhttps://www.pharmaradar360.com/article/bucks-county-biotech-hub-and-doylestown-hospital-land-state-grants-for-new-proje-8665c163a0e7a8bcPharmaRadar360en2026-09-18T14:00:00.000ZBucks County Biotech Hub and Doylestown Hospital Land State Grants for New Projectshttps://www.pharmaradar360.com/article/regional-signaling-controls-stem-cell-mediated-regeneration-in-an-invertebrate-c-04c94807eadc3cd8PharmaRadar360en2026-09-18T14:00:00.000ZRegional signaling controls stem cell-mediated regeneration in an invertebrate chordatehttps://www.pharmaradar360.com/article/collagen-i-promotes-cancer-cell-survival-via-amino-acid-import-and-mtorc1-s6-act-8a92da132dac0e52PharmaRadar360en2026-09-18T14:00:00.000ZCollagen I promotes cancer cell survival via amino acid import and mTORC1/S6 activationhttps://www.pharmaradar360.com/article/novo-targets-oral-macrocycles-with-1-4bn-orbis-partnership-6671ed6a26e6a1c2PharmaRadar360en2026-09-18T13:52:36.000ZNovo targets oral macrocycles with $1.4bn Orbis partnershiphttps://www.pharmaradar360.com/article/le-chu-de-toulouse-debute-les-inclusions-dans-l-etude-impulsion-41595d44ba4dcd69PharmaRadar360en2026-09-18T13:47:41.000ZLe CHU de Toulouse débute les inclusions dans l'étude IMPULSIONhttps://www.pharmaradar360.com/article/what-is-drawing-fresh-attention-to-takeda-pharmaceutical-tse-4502-8ed4853f5f8b35ebPharmaRadar360en2026-09-18T13:44:21.000ZWhat Is Drawing Fresh Attention To Takeda Pharmaceutical (TSE:4502)?https://www.pharmaradar360.com/article/inside-the-growing-world-of-biopharma-prediction-markets-765a66b0e486f7ccPharmaRadar360en2026-09-18T13:39:41.000ZInside the growing world of biopharma prediction marketshttps://www.pharmaradar360.com/article/veradermics-buy-before-the-catalysts-nyse-mane-90826b45a2962049PharmaRadar360en2026-09-18T13:39:00.000ZVeradermics: Buy Before The Catalysts (NYSE:MANE)https://www.pharmaradar360.com/article/shingles-can-cause-severe-chronic-pain-new-research-on-how-exosomes-alter-neuron-2a6301bdbff0f775PharmaRadar360en2026-09-18T13:33:48.000ZShingles Can Cause Severe Chronic Pain – New Research On How Exosomes Alter Neurons Offers Pathways To Treatmenthttps://www.pharmaradar360.com/article/4-westchester-fairfield-leaders-advocate-for-health-and-raise-funds-critical-for-78121da21d239558PharmaRadar360en2026-09-18T13:29:00.000Z4 Westchester/Fairfield leaders advocate for health and raise funds critical for fighting heart diseasehttps://www.pharmaradar360.com/article/seqens-brings-its-personal-care-and-custom-specialties-activities-together-withi-48e0fd6157eea57ePharmaRadar360en2026-09-18T13:27:31.000ZSEQENS brings its Personal Care and Custom & Specialties activities together within a single organization.https://www.pharmaradar360.com/article/fda-withdraws-publication-of-covid-shingles-vaccine-research-findings-0c9137b444e2e92aPharmaRadar360en2026-09-18T13:21:35.000ZFDA withdraws publication of COVID, shingles vaccine research findingshttps://www.pharmaradar360.com/article/reasons-to-add-west-pharmaceutical-stock-to-your-portfolio-now-a987741149fa9bd2PharmaRadar360en2026-09-18T13:21:00.000ZReasons to Add West Pharmaceutical Stock to Your Portfolio Nowhttps://www.pharmaradar360.com/article/suny-funding-to-advance-tech-that-could-improve-patient-care-9e34ce94de8cee0fPharmaRadar360en2026-09-18T13:15:09.000ZSUNY funding to advance tech that could improve patient carehttps://www.pharmaradar360.com/article/biotech-pre-market-movers-tcrt-meds-surge-xene-nuwe-sink-caabe3a95f74fd25PharmaRadar360en2026-09-18T13:13:00.000ZBiotech Pre-Market Movers: TCRT, MEDS Surge; XENE, NUWE Sinkhttps://www.pharmaradar360.com/article/aces-alumna-employs-biotech-to-create-sustainable-livestock-production-bcccea6733969c2cPharmaRadar360en2026-09-18T13:12:17.000ZACES alumna employs biotech to create sustainable livestock productionhttps://www.pharmaradar360.com/article/stanford-virtual-biotech-links-target-expression-patterns-to-higher-drug-success-4f2cc92095f808d2PharmaRadar360en2026-09-18T13:04:57.000ZStanford Virtual Biotech links target expression patterns to higher drug successhttps://www.pharmaradar360.com/article/state-fiscal-conditions-context-on-medicaid-budgets-for-fy-2027-a4d0ffddaeb7db7dPharmaRadar360en2026-09-18T13:00:00.000ZState Fiscal Conditions: Context on Medicaid Budgets for FY 2027https://www.pharmaradar360.com/article/chutes-ladders-legend-poaches-novartis-vet-to-boost-commercial-potential-e80965543b112e35PharmaRadar360en2026-09-18T12:53:06.000ZChutes & Ladders—Legend poaches Novartis vet to boost commercial potentialhttps://www.pharmaradar360.com/article/auszeichnungen-fur-herausragende-forschung-und-innovation-in-der-infektiologie-2e2b4d68c515c033PharmaRadar360en2026-09-18T12:46:20.000ZAuszeichnungen für herausragende Forschung und Innovation in der Infektiologiehttps://www.pharmaradar360.com/article/canaccord-genuity-group-increases-ultragenyx-pharmaceutical-nasdaq-rare-price-ta-7cfbe3170174b2c9PharmaRadar360en2026-09-18T12:45:11.000ZCanaccord Genuity Group Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $39.00https://www.pharmaradar360.com/article/west-pharma-to-cut-98-jobs-as-smartdose-production-winds-down-in-arizona-47ebb0bb9de0baddPharmaRadar360en2026-09-18T12:35:00.000ZWest Pharma to cut 98 jobs as SmartDose production winds down in Arizonahttps://www.pharmaradar360.com/article/unc-global-affairs-encourages-more-study-abroad-in-japan-b882c10bbd673b89PharmaRadar360en2026-09-18T12:34:51.000ZUNC Global Affairs encourages more study abroad in Japanhttps://www.pharmaradar360.com/article/scientists-discover-cells-that-cheat-death-and-rebuild-damaged-tissue-2ba232951401badcPharmaRadar360en2026-09-18T12:30:43.000ZScientists discover cells that cheat death and rebuild damaged tissuehttps://www.pharmaradar360.com/article/abbvie-highlights-new-real-world-data-supporting-the-effectiveness-of-vraylar-ca-4c1f376b38b218c5PharmaRadar360en2026-09-18T12:30:00.000ZAbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026https://www.pharmaradar360.com/article/lakewood-amedex-starts-phase-2a-trial-for-nu-3-to-treat-diabetic-foot-ulcers-wit-e4b94f11fe4c68f0PharmaRadar360en2026-09-18T12:24:15.000ZLakewood-Amedex starts Phase 2a trial for Nu-3 to treat diabetic foot ulcers with drug-resistant infectionshttps://www.pharmaradar360.com/article/jahresbericht-des-krebsregisters-der-kantone-zurich-zug-schaffhausen-und-schwyz-63636ce70813c644PharmaRadar360en2026-09-18T12:14:30.000ZJahresbericht des Krebsregisters der Kantone Zürich, Zug, Schaffhausen und Schwyzhttps://www.pharmaradar360.com/article/cantor-fitzgerald-forecasts-strong-price-appreciation-for-ultragenyx-pharmaceuti-a94686663212042bPharmaRadar360en2026-09-18T12:13:08.000ZCantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stockhttps://www.pharmaradar360.com/article/a-new-gel-for-infected-diabetic-foot-ulcers-is-ready-for-a-clinical-trial-9baca5ba6094011dPharmaRadar360en2026-09-18T12:13:00.000ZA new gel for infected diabetic foot ulcers is ready for a clinical trialhttps://www.pharmaradar360.com/article/lakewood-amedex-biotherapeutics-announces-irb-approval-and-clinical-site-readine-6c633ac91c89ca34PharmaRadar360en2026-09-18T12:13:00.000ZLakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcershttps://www.pharmaradar360.com/article/ligand-pharmaceuticals-owning-it-gives-you-a-stake-across-biotech-nasdaq-lgnd-a5490902b4f252f8PharmaRadar360en2026-09-18T12:06:16.000ZLigand Pharmaceuticals: Owning It Gives You A Stake Across Biotech (NASDAQ:LGND)https://www.pharmaradar360.com/article/countering-motor-neuron-degeneration-with-base-editing-155eca28b20c8601PharmaRadar360en2026-09-18T12:00:00.000ZCountering Motor Neuron Degeneration with Base Editinghttps://www.pharmaradar360.com/article/establishment-of-two-new-on-site-laboratories-approved-465c999c4a9c1229PharmaRadar360en2026-09-18T12:00:00.000ZEstablishment of two new On-site Laboratories approvedhttps://www.pharmaradar360.com/article/signatm-artist-and-signatm-artist-evo-b43f2d2ea4307776PharmaRadar360en2026-09-18T12:00:00.000ZSIGNA™ Artist and SIGNA™ Artist Evohttps://www.pharmaradar360.com/article/counterfeit-laser-hair-removal-and-therapy-devices-found-in-some-clinics-and-may-48182ef1961b6594PharmaRadar360en2026-09-18T12:00:00.000ZCounterfeit laser hair removal and therapy devices found in some clinics and may pose serious health riskshttps://www.pharmaradar360.com/article/ukri-space-lab-hosts-first-uk-pm-and-head-of-nato-meeting-484a0b72310be070PharmaRadar360en2026-09-18T11:33:37.000ZUKRI Space Lab hosts first UK PM and Head of NATO meetinghttps://www.pharmaradar360.com/article/abeona-therapeutics-congratulates-ultragenyx-on-u-s-fda-approval-of-fayuvitm-gen-08da3da710ebe595PharmaRadar360en2026-09-18T11:30:00.000ZAbeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)https://www.pharmaradar360.com/article/das-universitatsklinikum-heidelberg-ist-grundungsmitglied-von-medi-cus-bff2845ac3e34d06PharmaRadar360en2026-09-18T11:29:44.000ZDas Universitätsklinikum Heidelberg ist Gründungsmitglied von MEDI:CUShttps://www.pharmaradar360.com/article/china-unveils-a-new-five-year-plan-for-developing-pharmaceutical-industry-44919095069d11e6PharmaRadar360en2026-09-18T11:14:00.000ZChina unveils a new five-year plan for developing pharmaceutical industryhttps://www.pharmaradar360.com/article/pune-fda-action-rodent-droppings-live-cockroaches-found-in-new-poona-club-kitche-bb758074ecbcb628PharmaRadar360en2026-09-18T11:12:49.000ZPune FDA Action: Rodent Droppings, Live Cockroaches Found In New Poona Club Kitchen; Food Licence Suspendedhttps://www.pharmaradar360.com/article/why-executive-mfn-deals-aren-t-enough-q-a-with-joe-cunningham-48c869a29e6c3e7fPharmaRadar360en2026-09-18T11:10:17.000ZWhy Executive MFN Deals Aren't Enough: Q&A with Joe Cunninghamhttps://www.pharmaradar360.com/article/addressing-mfn-innovation-concerns-568aea26781afe55PharmaRadar360en2026-09-18T11:10:17.000ZAddressing MFN Innovation Concernshttps://www.pharmaradar360.com/article/shining-a-light-on-uterine-cancer-rising-incidence-and-mortality-persistent-ineq-b6df0ffb13807c1dPharmaRadar360en2026-09-18T11:00:17.000ZShining a Light on Uterine Cancer: Rising Incidence and Mortality, Persistent Inequitieshttps://www.pharmaradar360.com/article/bristol-myers-squibb-to-report-results-for-third-quarter-2026-on-october-29-2026-915d65a4fe2302cbPharmaRadar360en2026-09-18T10:59:00.000ZBristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026https://www.pharmaradar360.com/article/dr-reddy-s-laboratories-nse-drreddy-lenacapavir-licensing-agreement-update-d8133fe75a5e6799PharmaRadar360en2026-09-18T10:57:00.000ZDr Reddy's Laboratories (NSE:DRREDDY) Lenacapavir Licensing Agreement Updatehttps://www.pharmaradar360.com/article/exclusive-us-weighs-allowing-most-pharma-licensing-deals-with-china-sources-say-9eef7f5883b17b66PharmaRadar360en2026-09-18T10:55:03.000ZExclusive-US weighs allowing most pharma licensing deals with China, sources sayhttps://www.pharmaradar360.com/article/merck-receives-positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-padcev-e-9dda3e8e04d1e9eaPharmaRadar360en2026-09-18T10:55:00.000ZMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)https://www.pharmaradar360.com/article/chmp-recommends-eu-approval-of-roche-s-ocrevus-for-children-and-adolescents-with-7987b36e70396aa4PharmaRadar360en2026-09-18T10:45:00.000ZCHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosishttps://www.pharmaradar360.com/article/merck-launches-your-hive-of-whole-health-to-support-whole-person-care-for-people-6fb49d94bbe3b4f2PharmaRadar360en2026-09-18T10:45:00.000ZMerck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIVhttps://www.pharmaradar360.com/article/china-targets-3-5-trillion-yuan-pharmaceutical-industry-by-2030-ea3e6220b6b84bbfPharmaRadar360en2026-09-18T10:37:00.000ZChina Targets 3.5 Trillion Yuan Pharmaceutical Industry by 2030https://www.pharmaradar360.com/article/drugs-and-devices-reach-patients-before-required-safety-studies-finish-and-feder-548b50c37e1139d5PharmaRadar360en2026-09-18T10:31:07.000ZDrugs and Devices Reach Patients Before Required Safety Studies Finish and Federal Records Show Many Run Latehttps://www.pharmaradar360.com/article/a-sellas-immunotherapy-study-long-delayed-will-end-in-failure-4f39356374c8bccbPharmaRadar360en2026-09-18T10:28:36.000ZA Sellas immunotherapy study, long delayed, will end in failurehttps://www.pharmaradar360.com/article/investors-pour-over-30b-into-longevity-biotech-companies-8159bc55d8a873cePharmaRadar360en2026-09-18T10:15:47.000ZInvestors pour over $30B into longevity biotech companieshttps://www.pharmaradar360.com/article/nuvectis-pharma-haisco-licensing-deal-revitalises-biotech-but-no-rush-to-invest-9e5025881f0236a4PharmaRadar360en2026-09-18T10:15:05.000ZNuvectis Pharma:Haisco Licensing Deal Revitalises Biotech, But No Rush To Invest Now(NVCT)https://www.pharmaradar360.com/article/chicago-biotech-inomagen-lands-up-to-2-9m-for-gene-therapy-targeting-afib-2314e0a3b1c7a48dPharmaRadar360en2026-09-18T10:15:00.000ZChicago biotech Inomagen lands up to $2.9M for gene therapy targeting AFib